keyword
https://read.qxmd.com/read/38645602/plasma-cell-myeloma-in-a-9-year-old-male-case-report-and-literature-review
#21
Kato Ronald, Ambaru Jacinta, Ssebagala Umaru
KEY CLINICAL MESSAGE: Plasma cell myeloma is a rare entity in the pediatric population. The peak incidence is in the seventh decade, with less than 2% of cases occurring in patients under the age of 40. It is worth noting that any destructive bony lesion in a child should be investigated. ABSTRACT: Plasma cell myeloma (multiple myeloma) is the most common form of plasma cell neoplasm. It is a rare entity in young patients. The peak incidence is in the seventh decade, with less than 2% of cases occurring in patients under the age of 40...
April 2024: Clinical Case Reports
https://read.qxmd.com/read/38644993/multi-niche-human-bone-marrow-on-a-chip-for-studying-the-interactions-of-adoptive-car-t-cell-therapies-with-multiple-myeloma
#22
Delta Ghoshal, Ingrid Petersen, Rachel Ringquist, Liana Kramer, Eshant Bhatia, Thomas Hu, Ariane Richard, Reda Park, Jenna Corbin, Savi Agarwal, Abel Thomas, Sebastian Ramirez, Jacob Tharayil, Emma Downey, Frank Ketchum, Abigail Ochal, Neha Sonthi, Sagar Lonial, James N Kochenderfer, Reginald Tran, Mandy Zhu, Wilbur A Lam, Ahmet F Coskun, Krishnendu Roy
UNLABELLED: Multiple myeloma (MM), a cancer of bone marrow plasma cells, is the second-most common hematological malignancy. However, despite immunotherapies like chimeric antigen receptor (CAR)-T cells, relapse is nearly universal. The bone marrow (BM) microenvironment influences how MM cells survive, proliferate, and resist treatment. Yet, it is unclear which BM niches give rise to MM pathophysiology. Here, we present a 3D microvascularized culture system, which models the endosteal and perivascular bone marrow niches, allowing us to study MM-stroma interactions in the BM niche and model responses to therapeutic CAR-T cells...
April 12, 2024: bioRxiv
https://read.qxmd.com/read/38643954/psychoneuroimmunology-in-multiple-myeloma-and-autologous-hematopoietic-stem-cell-transplant-opportunities-for-research-among-patients-and-caregivers
#23
REVIEW
Lisa M Christian, Janice K Kiecolt-Glaser, Steve W Cole, Christin E Burd, Annelise A Madison, Stephanie J Wilson, Ashley E Rosko
Multiple myeloma (MM) is an incurable cancer and is the leading indication for autologous hematopoietic stem cell transplantation (HSCT). To be eligible for HSCT, a patient must have a caregiver, as caregivers play a central role in HSCT preparation and recovery. MM patients remain on treatment indefinitely, and thus patients and their caregivers face long-term challenges including the intensity of HSCT and perpetual therapy after transplant. Importantly, both patients and their caregivers show heightened depressive and anxiety symptoms, with dyadic correspondence evidenced and caregivers' distress often exceeding that of patients...
April 19, 2024: Brain, Behavior, and Immunity
https://read.qxmd.com/read/38643632/transcriptome-of-bone-marrow-derived-stem-cells-reveals-new-inflammatory-mediators-related-to-increased-survival-in-patients-with-multiple-myeloma
#24
JOURNAL ARTICLE
Stefania Tagliari de Oliveira, Renata Binato, Geise Ellen Broto, Erika Tomie Takakura, Leticia Navarro Gordan Ferreira Martins, Eliana Abdelhay, Carolina Panis
Although multiple myeloma (MM) is a neoplasm that leads affected individuals to death, little is known about why some patients survive much longer than others. In this context, we investigated the transcriptomic profile of bone marrow hematopoietic stem cells obtained from MM patients and compared the clinical outcomes of death and survival six months after bone marrow transplantation. The leukapheresis products of 39 patients with MM eligible for autologous transplantation were collected and analyzed. After extraction, the RNA was analyzed using the GeneChip Human Exon 1...
April 20, 2024: Cytokine
https://read.qxmd.com/read/38643494/ras-raflandscape-in-monoclonal-plasma-cell-conditions
#25
JOURNAL ARTICLE
Anaïs Schavgoulidze, Jill Corre, Mehmet K Samur, Celine Mazzotti, Luka Pavageau, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Margaret Macro, Karim Belhadj, Murielle Roussel, Sabine Brechignac, Lydia Montes, Denis Caillot, Laurent Frenzel, Philippe Rey, Jean Marc Schiano, Thomas Chalopin, Caroline Jacquet, Valentine Richez, Frederique Orsini Piocelle, Jean Fontan, Salomon Manier, Ludovic Martinet, Adam Sciambi, Mohamad Mohty, Hervé Avet-Loiseau
Multiple Myeloma (MM) is characterized by a huge heterogeneity at the molecular level. The RAS/RAF pathway is the most frequently mutated, in about 50% of the patients. However, these mutations are frequently subclonal, suggesting a secondary event. Since these genes are part of our routine next-generation sequencing (NGS) panel, we analyzed >10,000 patients with different plasma cell disorders in order to describe the RAS/RAF landscape. In this large cohort of patients, almost 61% of the patients presented a RAS/RAF mutation at diagnosis or relapse, but much lower frequencies in pre-symptomatic cases...
April 21, 2024: Blood
https://read.qxmd.com/read/38643346/a-phase-i-trial-evaluating-the-addition-of-lenalidomide-to-patients-with-relapsed-refractory-multiple-myeloma-progressing-on-ruxolitinib-and-methylprednisolone
#26
JOURNAL ARTICLE
James R Berenson, Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Matthew Brobeck, Regina Swift, Benjamin M Eades, Sean Bujarski, Yohana Sebhat, Rudra Ray, Susanna Kim, Ashley Del Dosso, Robert Vescio
BACKGROUND: Ruxolitinib (RUX), an orally administered selective Janus kinase 1/2 inhibitor, has received approval for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. We have previously demonstrated the anti-multiple myeloma effects of RUX alone and in combination with the immunomodulatory agent lenalidomide (LEN) and glucocorticosteroids both pre-clinically and clinically. OBJECTIVE: This study aims to evaluate whether LEN can achieve clinical activity among patients with multiple myeloma progressing on the combination of RUX and methylprednisolone (MP)...
April 20, 2024: Targeted Oncology
https://read.qxmd.com/read/38643278/bispecific-car-t-cell-therapy-targeting-bcma-and-cd19-in-relapsed-refractory-multiple-myeloma-a-phase-i-ii-trial
#27
JOURNAL ARTICLE
Ming Shi, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Junnian Zheng, Jiang Cao
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 CAR T cells targeting BCMA/CD19 and evaluate antimyeloma activity in vitro and in vivo. Preclinical results indicate that BC19 CAR specifically recognize target antigens, and BC19 CAR T cells mediate selective killing of BCMA or CD19-positive cancer cells...
April 20, 2024: Nature Communications
https://read.qxmd.com/read/38643029/soho-state-of-the-art-updates-and-next-questions-updates-on-building-your-car-t-cell-program
#28
REVIEW
Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima
Chimeric antigen receptor T-cell (CAR-T) therapy has significantly impacted treatment algorithms and clinical outcomes for a variety of patients with hematologic malignancies over the past decade. The field of cellular immunotherapy is currently experiencing a rapid expansion of the number of patients eligible for CAR-T therapies as approvals are being seen in earlier lines of therapy. With the expanded patients eligible for these therapies, more treatment centers will be necessary to keep up with demand. Building a cellular therapy program can be a daunting task, and therefore, we present our experience with building a clinical cellular therapy program...
March 18, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38642856/glyr1-transcriptionally-regulates-per3-expression-to-promote-the-proliferation-and-migration-of-multiple-myeloma
#29
JOURNAL ARTICLE
Xiao Yan, Kaihong Xu, Zhijuan Xu, Cong Shi, Binbin Lai, Hao Wu, Shujun Yang, Lixia Sheng, Keting Wang, Yuhan Zheng, Guifang Ouyang, Di Yang
Period circadian regulator 3 (PER3) functions as a tumor suppressor in various cancers. However, the role of PER3 in multiple myeloma (MM) has not been reported yet. Through this study, we aimed to investigate the potential role of PER3 in MM and the underlying mechanisms. RT-qPCR and western blotting were used to determine the mRNA and protein expression levels of PER3. Glyoxylate reductase 1 homolog (GLYR1) was predicted to be a transcription factor of PER3. The binding sites of GLYR1 on the promoter region of PER3 were analyzed using UCSC and confirmed using luciferase and chromatin immunoprecipitation assays...
April 18, 2024: Genomics
https://read.qxmd.com/read/38642197/real-world-data-on-therapies-for-relapsed-or-refractory-multiple-myeloma-key-data-from-ash-2023-a-podcast
#30
JOURNAL ARTICLE
Luciano J Costa, Paula Rodriguez-Otero
Immunotherapies have significantly improved outcomes in patients with multiple myeloma yet maintaining a durable response in heavily pretreated patients remains challenging. Therapies that target B cell maturation antigen (BCMA) provide additional treatment options in patients whose disease becomes refractory to several drug classes in early lines of therapy. Clinical trial data from selected patient populations and controlled settings are complemented by real-world data (RWD) from actual clinical practice...
April 20, 2024: Advances in Therapy
https://read.qxmd.com/read/38642035/melan-a-immunolabeling-in-canine-extramedullary-plasmacytomas
#31
JOURNAL ARTICLE
Lukas Schuwerk, Anastasiia Ulianytska, Wolfgang Baumgärtner, Wencke Reineking
Histologic diagnosis of less well-differentiated cases of canine extramedullary plasmacytomas (CEMPs) may require immunohistochemical confirmation to discriminate these tumors from other round cells tumors including lymphoma, cutaneous histiocytoma, and amelanotic melanomas. CEMPs are characterized by widespread immunoreactivity for multiple myeloma 1 (MUM1) antigen and λ light chains, while the melanocytic marker melan-A has been reported to yield negative results. Here, 33 randomly selected CEMPs, 20 melanocytomas, and 20 malignant melanomas were immunohistochemically tested for MUM1, melan-A, and PNL2...
April 20, 2024: Veterinary Pathology
https://read.qxmd.com/read/38641734/single-cell-multiomic-dissection-of-response-and-resistance-to-chimeric-antigen-receptor-t-cells-against-bcma-in-relapsed-multiple-myeloma
#32
JOURNAL ARTICLE
Michael Rade, Nora Grieb, Ronald Weiss, Jaren Sia, Luise Fischer, Patrick Born, Andreas Boldt, Stephan Fricke, Paul Franz, Jonathan Scolnick, Lakshmi Venkatraman, Stacy Xu, Christina Kloetzer, Simone Heyn, Anne Sophie Kubasch, Ronny Baber, Song Yau Wang, Enrica Bach, Sandra Hoffmann, Jule Ussmann, Birthe Schetschorke, Saskia Hell, Sebastian Schwind, Klaus H Metzeler, Marco Herling, Madlen Jentzsch, Georg-Nikolaus Franke, Ulrich Sack, Ulrike Köhl, Uwe Platzbecker, Kristin Reiche, Vladan Vucinic, Maximilian Merz
Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse. Differences between responders and nonresponders were identified at the time of leukapheresis...
April 19, 2024: Nature Cancer
https://read.qxmd.com/read/38641486/soho-state-of-the-art-updates-and-next-questions-diagnosis-and-management-of-monoclonal-gammopathy-of-undetermined-significance-and-smoldering-multiple-myeloma
#33
REVIEW
Timothy Schmidt, Zhubin Gahvari, Natalie S Callander
Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma...
March 16, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38641485/mantle-cell-lymphoma-under-the-scope-of-personalized-medicine-perspective-and-directions
#34
REVIEW
Lara Gallucci Figorelle, Peterson Tiago Galvão, Felipe Matheus Ribeiro de Lima, Patricia Marimon, Nathalia Pentagna, Cristiane Milito, Rony Schaffel, Katia Carneiro
Mantle cell lymphoma (MCL) is a rare, incurable non-Hodgkin's lymphoma characterized by naive B cells infiltrating the lymphoid follicle's mantle zone. A key feature of MCL is the cytogenetic abnormality t(11;14) (q13:q14), found in 95% of cases, leading to Cyclin D1 overexpression resulting in uncontrolled cell cycle progression and genetic instability. Occasionally, Cyclin D2 or D3 overexpression can substitute for Cyclin D1, causing similar effects. The transcription factor SOX11 is a hallmark of classical Cyclin D1-positive MCL and also in cases without the typical t(11;14) abnormality, making it an important diagnostic marker...
March 27, 2024: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38639848/cytomegalovirus-infection-during-daratumumab-therapy-in-patients-with-newly-diagnosed-multiple-myeloma
#35
JOURNAL ARTICLE
Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Moe Nomura-Yogo, Yuki Oda, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Tadao Ishida
The introduction of daratumumab has improved treatment outcomes for multiple myeloma (MM). However, infectious complications are a concern in patients receiving daratumumab. Although some reports have explored the association between daratumumab and cytomegalovirus (CMV) infection, most of these have focused on relapsed or refractory cases, and few describe patients with newly diagnosed MM (NDMM). In this study, we retrospectively analyzed CMV infections in 53 patients with NDMM who received daratumumab as induction therapy...
April 19, 2024: International Journal of Hematology
https://read.qxmd.com/read/38638843/daratumumab%C3%A2-resistant-multiple-myeloma-with-extramedullary-disease-successfully-treated-with-combination-elotuzumab-pomalidomide-and-dexamethasone-a-case-report
#36
Masataka Sakashita, Naohi Sahara, Jun Aoki, Takashi Matsunaga, Seiichiro Kobayashi, Shinsuke Kitahara, Tomoki Fujii, Nobuhiro Ohno
Despite the emergence of monoclonal antibodies, the prognosis of patients with multiple myeloma (MM) with extramedullary disease remains poor. The present report describes a rare case of daratumumab-refractory MM that was successfully treated with elotuzumab, pomalidomide and dexamethasone. A 66-year-old male patient diagnosed with MM was treated with bortezomib, lenalidomide and dexamethasone, followed by high-dose chemotherapy and autologous stem cell transplantation. Thereafter, the patient was treated with lenalidomide and dexamethasone as maintenance therapy...
June 2024: Oncology Letters
https://read.qxmd.com/read/38637658/perception-predicts-patient-response-and-resistance-to-treatment-using-single-cell-transcriptomics-of-their-tumors
#37
JOURNAL ARTICLE
Sanju Sinha, Rahulsimham Vegesna, Sumit Mukherjee, Ashwin V Kammula, Saugato Rahman Dhruba, Wei Wu, D Lucas Kerr, Nishanth Ulhas Nair, Matthew G Jones, Nir Yosef, Oleg V Stroganov, Ivan Grishagin, Kenneth D Aldape, Collin M Blakely, Peng Jiang, Craig J Thomas, Cyril H Benes, Trever G Bivona, Alejandro A Schäffer, Eytan Ruppin
Tailoring optimal treatment for individual cancer patients remains a significant challenge. To address this issue, we developed PERCEPTION (PERsonalized Single-Cell Expression-Based Planning for Treatments In ONcology), a precision oncology computational pipeline. Our approach uses publicly available matched bulk and single-cell (sc) expression profiles from large-scale cell-line drug screens. These profiles help build treatment response models based on patients' sc-tumor transcriptomics. PERCEPTION demonstrates success in predicting responses to targeted therapies in cultured and patient-tumor-derived primary cells, as well as in two clinical trials for multiple myeloma and breast cancer...
April 18, 2024: Nature Cancer
https://read.qxmd.com/read/38636951/a-prognostic-survival-model-incorporating-patient-reported-outcomes-for-transplant-ineligible-patients-with-multiple-myeloma
#38
JOURNAL ARTICLE
Hira Mian, Hsien Seow, Amaris K Balitsky, Matthew C Cheung, Anastasia Gayowsky, Jason Tay, Tanya M Wildes, Arleigh McCurdy, Alissa Visram, Irwindeep Sandhu, Rinku Sutradhar
Developing prognostic tools specifically for patients themselves represents an important step in empowering patients to engage in shared decision-making. Incorporating patient-reported outcomes may improve the accuracy of these prognostic tools. We conducted a retrospective population-based study of transplant-ineligible (TIE) patients with multiple myeloma (MM) diagnosed between January 2007 and December 2018. A multivariable Cox regression model was developed to predict the risk of death within 1-year period from the index date...
April 18, 2024: Oncologist
https://read.qxmd.com/read/38636896/metronomic-chemotherapy-in-hematology-lessons-from-preclinical-and-clinical-studies-to-build-a-solid-rationale-for-future-schedules
#39
JOURNAL ARTICLE
Marta Banchi, Maria Christina Cox, Guido Bocci
Metronomic chemotherapy (mCHEMO), based on frequent, regular administration of low, but pharmacologically active drug doses, optimizes antitumor efficacy by targeting multiple targets and reducing toxicity of antineoplastic drugs. This minireview will summarize preclinical and clinical studies on cytotoxic drugs given at weekly, daily, or at continuous metronomic schedules alone or in combination with novel targeted agents for hematological malignancies, including lymphoma, multiple myeloma, and leukaemia. Most of the preclinical in vitro and in vivo studies have reported a significant benefit of both mCHEMO monotherapy and combinatorial regimens compared with chemotherapy at the maximum tolerated dose...
April 16, 2024: Cancer Letters
https://read.qxmd.com/read/38636694/an-up-conversion-fluorescence-lateral-flow-immunoassay-for-rapid-detection-of-daratumumab-in-serum-protein-electrophoresis-clinical-samples
#40
JOURNAL ARTICLE
Yajing Liu, Yanru Tao, Priscilla S-W Yeung, Mengyan Lu, Jing Liu, Fang Yu, Run-Zhang Shi, Ruben Yiqi Luo
BACKGROUND: Daratumumab (DARA) is a commonly used monoclonal antibody (mAb) drug for the treatment of multiple myeloma (MM). Its appearance as a visible abnormal band in the γ-region of a serum protein electrophoresis (SPEP) gel may interfere with the SPEP result interpretation. With the advantages of portability and rapid testing capabilities, up-conversion fluorescence lateral-flow immunoassay (LFA) can be an ideal solution to detect DARA interference. METHODS: An up-conversion fluorescence LFA strip was designed and constructed to perform semi-quantitative DARA testing in clinical samples...
April 16, 2024: Clinica Chimica Acta; International Journal of Clinical Chemistry
keyword
keyword
61997
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.